DK3749353T3 - Nemolizumab til behandling af atopisk dermatitis med moderat til svær excoriation - Google Patents

Nemolizumab til behandling af atopisk dermatitis med moderat til svær excoriation

Info

Publication number
DK3749353T3
DK3749353T3 DK19710488.8T DK19710488T DK3749353T3 DK 3749353 T3 DK3749353 T3 DK 3749353T3 DK 19710488 T DK19710488 T DK 19710488T DK 3749353 T3 DK3749353 T3 DK 3749353T3
Authority
DK
Denmark
Prior art keywords
nemolizumab
excoriation
moderate
severe
treatment
Prior art date
Application number
DK19710488.8T
Other languages
Danish (da)
English (en)
Inventor
Nabil Kerrouche
Keiko Hirokawa
Ryosuke Mihara
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Application granted granted Critical
Publication of DK3749353T3 publication Critical patent/DK3749353T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19710488.8T 2018-02-09 2019-02-08 Nemolizumab til behandling af atopisk dermatitis med moderat til svær excoriation DK3749353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
DK3749353T3 true DK3749353T3 (da) 2025-09-01

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19710488.8T DK3749353T3 (da) 2018-02-09 2019-02-08 Nemolizumab til behandling af atopisk dermatitis med moderat til svær excoriation

Country Status (23)

Country Link
US (2) US12435147B2 (https=)
EP (2) EP4644424A3 (https=)
JP (3) JP7777921B2 (https=)
CN (1) CN112040976A (https=)
AU (2) AU2019219608B2 (https=)
BR (1) BR112020016144A2 (https=)
CA (1) CA3090062A1 (https=)
CL (1) CL2020002050A1 (https=)
DK (1) DK3749353T3 (https=)
ES (1) ES3049513T3 (https=)
FI (1) FI3749353T3 (https=)
HR (1) HRP20251101T1 (https=)
IL (1) IL276524A (https=)
LT (1) LT3749353T (https=)
MX (1) MX2020008193A (https=)
PH (1) PH12020551185A1 (https=)
PL (1) PL3749353T3 (https=)
PT (1) PT3749353T (https=)
RU (1) RU2758378C1 (https=)
SG (1) SG11202007558YA (https=)
SI (1) SI3749353T1 (https=)
TW (1) TWI856006B (https=)
WO (1) WO2019155427A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025095100A1 (ja) * 2023-11-02 2025-05-08 マルホ株式会社 医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
SG10202112628UA (en) * 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
CL2020002050A1 (es) 2020-12-11
IL276524A (en) 2020-09-30
HRP20251101T1 (hr) 2025-11-21
JP2021512917A (ja) 2021-05-20
TW201941800A (zh) 2019-11-01
BR112020016144A2 (pt) 2020-12-15
WO2019155427A1 (en) 2019-08-15
PH12020551185A1 (en) 2021-05-17
SG11202007558YA (en) 2020-09-29
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
EP4644424A2 (en) 2025-11-05
TW202448919A (zh) 2024-12-16
RU2758378C1 (ru) 2021-10-28
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
US20200385476A1 (en) 2020-12-10
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
JP2023182632A (ja) 2023-12-26
AU2019219608B2 (en) 2025-10-16
CN112040976A (zh) 2020-12-04
CA3090062A1 (en) 2019-08-15
SI3749353T1 (sl) 2025-10-30
JP7777921B2 (ja) 2025-12-01
JP2025176134A (ja) 2025-12-03
TWI856006B (zh) 2024-09-21
EP3749353B1 (en) 2025-07-30
US20260008859A1 (en) 2026-01-08
PT3749353T (pt) 2025-10-14
EP4644424A3 (en) 2026-01-14
FI3749353T3 (fi) 2025-09-10

Similar Documents

Publication Publication Date Title
CY2024013I1 (el) Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3668509T3 (da) Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
DK3515937T3 (da) Behandling af refraktorisk migræne
DK3612215T3 (da) Sammensætninger til behandling af lungeinflammation
DK3120831T3 (da) Topikal levering af hudsammensætninger med lav ph
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3468997T5 (da) Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3193880T3 (da) Hæmning af den transiente receptor-potential-A1-ionkanal
DK3524255T3 (da) Sammensætning til behandling af acne
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3728410T3 (da) Fremgangsmåde til behandling af lignocelluloseholdig biomasse
DK3579826T3 (da) Fremgangsmåder til behandling af cdkl5-lidelser med forbindelsen ov329
DK3641888T3 (da) Plasminogenbehandling af tilstande forbundet med pai-1-overekspression
KR101666864B9 (ko) 우수의 비점오염물질 처리장치
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
LT3368044T (lt) Kepenų steatozės, susijusios su oligo-ovuliacija, gydymas
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
DK3856213T3 (da) Fremgangsmåder til behandling af infektioner under anvendelse af bakterier
DK3727429T3 (da) Behandling af autonomiske lidelser med botulinumtoxin
DK3253406T5 (da) Sammensætninger til behandling af granulomatose med polyangiitis